research use only

Lithium carbonate Dopamine Receptor modulator

Name: Lithium carbonate
Brand: Selleck Chemicals
SKU: S4933
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.S4933

Lithium carbonate (Li2CO3) is an inorganic compound that is valuable and effective agent in the treatment and prophylaxis of mood disorders, particularly bipolar disorder (BD). This compound is able to alter D2 dopamine receptors response.

Chemical Structure

Molecular Weight: 73.89

Jump to

Quality Control

Batch: S493301 Water]＜1 mg/mL]false]Ethanol]＜1 mg/mL]false]5%TFA]33mg/ml mg/mL]false Purity: 98%

Cited in Nature Medicine for its top-tier quality
COA
SDS/MSDS
Datasheet

Related Targets	Adrenergic Receptor AChR 5-HT Receptor COX Calcium Channel Histamine Receptor GABA Receptor TRP Channel Cholinesterase (ChE) GluR
Other Dopamine Receptor Inhibitors	MPTP Hydrochloride Trifluoperazine Trifluoperazine 2HCl Penfluridol Rotundine Domperidone Sulpiride Azaperone ONC206 SCH-23390 hydrochloride

Solubility

In vitro
Batch:

Water : ＜1 mg/mL

Ethanol : ＜1 mg/mL

5%TFA : 33mg/ml mg/mL

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Clear solution	5%TFA 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.65mg/ml (22.33mM)	Taking the 1 mL working solution as an example, add 50 μL of 33 mg/ml clarified TFA stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	73.89	Formula	CLi₂O₃	Storage (From the date of receipt)	3 years-21°C powder
CAS No.	554-13-2	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	Li2CO3			SMILES	[Li+].[Li+].C(=O)([O-])[O-]

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

References	[1] https://pubmed.ncbi.nlm.nih.gov/28953792/ [2] https://pubmed.ncbi.nlm.nih.gov/12427114/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-08-06)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07750925	NOT_YET_RECRUITING	Healthy; Bipolar	Northumbria University	2026-08-01
NCT06184581	RECRUITING	Bipolar II Disorder	University Hospital Bispebjerg and Frederiksberg	2024-05-08	PHASE4
NCT06776848	RECRUITING	Proven Pathogenic or Probably Pathogenic TBR1 Variant	Centre Hospitalier Universitaire Dijon	2025-09-12	PHASE1; PHASE2
NCT05814640	RECRUITING	Depression; Sequestra	First Affiliated Hospital of Chongqing Medical University	2023-02-20	PHASE1; PHASE2
NCT07540338	RECRUITING	Bipolar I Disorder	Alzamend Neuro, Inc.	2026-05-11	PHASE1; PHASE2
NCT05593627	UNKNOWN	Heart Valve Surgery	China Medical University, China	2023-07-01	PHASE4

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):